Can we customize chemotherapy? individualizing cytotoxic regimens in advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 2, 2008, Pages

  Rosell, Rafael ^a   Manegold, Christian ^b   Moran, Teresa ^a   Garrido, Pilar ^c   Blanco, Remei ^d   Lianes, Pilar ^e   Stahel, Rolf ^f   Trigo, Jose Manuel ^g   Wei, Jia ^a   Taron, Miquel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL DE TERRASSA   (Spain)

^e HOSPITAL DE MATARÓ   (Spain)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Cisplatin; ERCC1; Pharmacogenomics; Platinum; RRM1; Xeroderma pigmentosum

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MESSENGER RNA; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DRUG INHIBITION; DRUG MECHANISM; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROTOXICITY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDONUCLEASES; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; RNA, MESSENGER;

EID: 63849299235     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.012     Document Type: Article

References (40)

1. Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study [published correction appears in Lancet Oncol 2007; 8:868]. Lancet Oncol 2007; 8:773-83.
2. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-16.
3. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-304.
4. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-91.
5. Geleziunas R, McQuillan A, Malapetsa A, et al. Increased DNA synthesis and repair- enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 1991; 83:557-64.
6. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94:703-8.
7. Cummings M, Higginbottom K, McGurk CJ, et al. XPA versus ERCC1 as chemosen- sitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 2006; 72:166-75.
8. Beljanski V, Marzilli LG, Doetsch PW DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol Pharmacol 2004; 65:1496-506.
9. Evert BA, Salmon TB, Song B, et al. Spontaneous DNA damage in Saccharomyces cerevisiae elicits phenotypic properties similar to cancer cells. J Biol Chem 2004; 279:22585-94.
10. de Laat WL, Jaspers NGJ, Hoeijmakers JHJ. Molecular mechanism of nucleotide excision repair. Genes Dev 1999; 13:768-85.
11. Rosell R, Crino L, Danenberg K, et al. Targeted therapy in combination with gem- citabine in non-small cell lung cancer. Semin Oncol 2003; 30(4 suppl 10):19-25.
12. Rosell R, Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003; 10:297-305.
13. Rosell R, Taron M, Ariza A, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004; 31(1 suppl 1):20-7.
14. Wijnhoven SWP, Hoogervorst EM, de Waard H, et al. Tissue specific mutagenic and carcinogenic responses in NER defective mouse models. Mutat Res 2007; 614:77-94.
15. Ito S, Kuraoka I, Chymkowitch P, et al. XPG stabilizes TFIIH, allowing transactiva- tion of nuclear receptors: implications for Cockayne syndrome in XP-G/CS patients. Mol Cell 2007; 26:231-43.
16. Rosell R, Mendez P, Isla D, et al. Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007; 2:1063-6.
17. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62:4899-902.
18. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004; 24:5776-87.
19. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cispla- tin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21:3207-13.
20. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25:2747-54.
21. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-103.
22. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non- Small Cell Lung Cancer Study Group [published correction appears in J Clin Oncol 2004; 22:209]. J Clin Oncol 2000; 18:2354-62.
23. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small- cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18:131-5.
24. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-24.
25. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-25.
26. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10:4215s-9s.
27. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:2741-6.
28. Le Page F, Randrianarison V, Marot D, et al. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000; 60:5548-52.
29. Abbott DW, Thompson ME, Robinson-Benion C, et al. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999; 274:18808-12.
30. Husain A, He G, Venkatraman ES, et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58:1120-3.
31. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275:23899-903.
32. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63:6221-8.
33. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96:1659-68.
34. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13:2443-9.
35. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
36. Choy H, Pass H, Rosell R, et al. Lung cancer. In: Chang A, Ganz PA, Hayes DF, et al, eds. Oncology: An Evidence-Based Approach. New York, NY: Springer Science + Business Media, Inc; 2006:545-621.
37. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-91.
38. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22:3548-53.
39. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91.
40. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-8.